Acrivon stockholders elect three Class III directors and ratify PwC as auditor

Acrivon Therapeutics, Inc.

Quorum of 29,659,010 shares (94.59%) present at 2025 annual meeting on June 13.
Peter Blume-Jensen (26,612,623 for), Derek DiRocco (24,606,548), Santhosh Palani (26,246,868) elected as Class III directors.
Ratification of PricewaterhouseCoopers LLP as auditor for FY2025: 29,653,924 for, 3,673 against, 1,413 abstain.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.